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Osteoarthritis (OA) is themost common joint disorder in the world. Among themechanisms involved in osteoarthritis, biomarkers
(cytokines profile)may be related to pain and pain intensity, functional capacity, and pressure pain thresholds (PPT).Thus, the study
of these relationships may offer useful information about pathophysiology and associated mechanisms involved in osteoarthritis.
Therefore, the objective of this studywas to investigate the seric concentration of pro (IL-6, IL-8, andTNF-𝛼) and anti-inflammatory
(IL-10) cytokines in patients with painful knee osteoarthritis and to correlate the levels of these biomarkers with the patients’
functional capacity and pressure pain threshold (PPT) values.
1. Introduction
Osteoarthritis (OA) is the most common joint disorder in
the world [1]. In the United States, the symptomatic knee OA
occurs in 10% of the male and 13% of the female population
with 60 years of age or more, with an estimated financial
burden of US$ 47.8 billion annually [2, 3]. In Brazil, this
disease is estimated to affect 6% to 12% of the adults with
more than one third of those aged 65 years or over [4]. Due
to the current trend of population aging and the increasing
prevalence of obesity, it is estimated that the number of people
suffering from knee OA will probably increase in the coming
years [5] with substantial reduction in quality of life for the
individual and massive costs for societies.
Different mechanisms may underlie the heterogeneous
and multifactorial presentation of OA and inflammation is
considered as one of the factors involved at some stages in the
OAprogression.The inflammatory processmay be associated
with alterations in the cytokines profile (e.g., interleukin-
6) [6]. In addition, specific cytokines may provoke damage
of the extracellular matrix of the joint tissue [7]. Some
cytokines may act as biochemical markers of OA severity
and pain [8]. Recent studies have indicated that specific pain
mechanisms in OA may relate to biomarkers associated with
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cartilage and bone degradation [9]. Yet articular cartilage
and subchondral bone damage are key factors in OA and
can be assessed by a variety of new biomarkers [10] such
as C-telopeptide of Type I collagen (CTX-I), CTX-II, Type
III collagen N-propeptide, and matrix metalloproteinase
(MMP)mediated degradation fragments of connective tissue
turnover (C1M and C2M) and synovium (C3M) connective
tissue turnover [11]. Ishijima et al. [12] showed that pain
and Type II collagen degradation (sC2C and uCTX-II) and
formation (sCPII), bone resorption (uNTx), and hence, for
example, synovitis may contribute to joint pain. Another
novel biomarker specific of MMP cleavage is the CRPM that
reflects local inflammation, whereas circulating, uncleaved
C-reactive protein (CRP) reflects systemic inflammation [13].
It is therefore of relevance to investigate how joint damage,
measured by these novel disease related biomarkers, is related
to pain mechanisms. Further, many authors have reported
on the effects of different variables, such as functional
performance [14], obesity [15], clinical aspects [16], and radi-
ological severity of OA [6], on the serum or intra-articular
levels of cytokines. In obesity, more and more studies have
shown hypersensitivity to pain and that those individuals are
more vulnerable to developing pain possibly due to the low
inflammatory processes initiated by cytokine release from
adipose tissue [17]. It has been already shown that pain in
knee OA patients may be associated with generalized pain
sensitization rather than peripheral inflammation and injury
[18–21]. It is well known that joint damage in the individual
OA patient is not strongly associated with pain [22, 23],
suggesting many other factors are involved in driving the
clinical manifestations in OA.
To further address this issue, the current study (1) inves-
tigated serum concentrations of proinflammatory cytokines
(IL-6, IL-8, and TNF-𝛼) and an anti-inflammatory cytokine
(IL-10) in OA patients (with painful knee osteoarthritis)
and healthy controls and (2) correlated these serum levels
with pain intensity, functional capacity, and pressure pain
thresholds (PPTs).
2. Method
This study was approved by the Ethics Committee for Anal-
ysis of Research Projects (CAPPesq), Hospital of Clinics of
University of Sa˜o Paulo Medical School, Sa˜o Paulo, Brazil,
research protocol CAPPesq 0131/10. All participants were
informed about the study procedure and they all signed
an informed consent. The procedures that followed were
in accordance with the ethical standards of the responsible
committee on human experimentation (institutional and
national) andwith theHelsinkiDeclaration of 1975, as revised
in 2000.
2.1. Study Population. The recruitment of 101 subjects was
done through referrals from various departments of the
Hospital of Clinics and via contact with friends or family
members who volunteered to participate.
Knee OA subjects (𝑁 = 53) were enrolled if they
had the following: age ≥ 60 years, diagnosis of knee OA
according to the American College of Rheumatology criteria
and Kellgren/Lawrence scale grades of 2–4 [24, 25], and
moderate to severe pain (visual analogue scale (VAS) > 4),
as general averaged level of pain experienced during the day
for the past month, lasting ≥ 3 months.
Healthy volunteers without any pain (𝑁 = 48) partic-
ipated as controls. Those who had any rheumatic disease,
fibromyalgia and other chronic painful condition, a history
of malignancy, psychiatric disorder, or previous knee surgery
were not included in the study.
2.2. Assessment of Function and Pain. Participants answered
the Western Ontario and McMaster Universities Arthritis
Index (WOMAC) questionnaire for the assessment of pain
and function during daily activities [26].
Pain intensity was assessed using the 10 cm VAS ruler
graded from zero (no pain) to ten (average pain intensity
during the past 48 hours, during daily activities).
The pressure pain threshold (PTT) was measured by a
pressure algometer (Pain Diagnostics, Great Neck, NY, USA)
having a hard rubber 1 cm2 at the end of the apparatus. The
pressure was applied perpendicular to the skin at a constant
speed (1 Kg/s) and the patients indicated when they felt pain.
The reading is expressed in kg/cm2.
Pressure pain thresholds were assessed over vastus medi-
alis, adductor longus, rectus femoris, vastus lateralis, tibialis
anterior, peroneus longus, iliacus, sartorius, gracilis, quadra-
tus lumborum, and popliteus as previously described [18].
For this evaluation, the subject remained supine and prone
and in the lateral position for better evaluation. We have
not performed measures over the knee joints. In addition,
PPT values were assessed over the ligaments located over
the supraspinous ligaments (L) between L1-L2, L2-L3, L3-
L4, L4-L5, and L5-S1 and sacral (S) areas S1-S2. During this
assessment, the volunteer lied in the lateral decubitus position
with hip flexion and the evaluator applied the pressure
directly over the region. The pinch and roll maneuver at the
L1, L2, L3, L4, L5, S1, and S2 dermatomes was done to evaluate
subcutaneous hyperalgesia [27]. Except for the supraspinous
ligaments and the L5–S1 and S1–S2 sacral areas (6 sites), all
measurements were done bilaterally [28].
2.3. Blood Samples. Serum concentrations of proinflam-
matory cytokines (IL-6, IL-8, and TNF-𝛼) and an anti-
inflammatory cytokine (IL-10) were collected by blood sam-
ples (5mL), taken from the antecubital vein between 8:00
am and 11:00 am. A Vacutainer tube, without the addition
of anticoagulants, was used in order to obtain serum after
the centrifugation process at 500 g, 4∘C. Samples of sera
were separated in 100 uL aliquots in Eppendorf cryotube
and stored at −80∘C until processing. Data was obtained by
measuring the fluorescence intensity. Human Inflammatory
Cytokines Kit (BDTM Bioscience CBA Cytometric Bead
Array, San Jose, CA) was used to quantitatively measure
serum concentrations of interleukin-6 (IL-6), interleukin-8
(IL-8), and tumor necrosis factor (TNF-𝛼) according to the
manufacturer’s instructions. Individual cytokine concentra-
tions (pg/mL) were computed using the standard reference
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curve of CELLQUEST and CBA software. The reading of
the serum samples was performed by the cytometer FACS
Calibur (BD Biosciences, USA) from the Laboratory of Med-
ical Investigation (LIM 56), University of Sa˜o Paulo School
of Medicine. The serum measurements of proinflammatory
cytokines (IL-6, IL-8, and TNF-𝛼) and an anti-inflammatory
cytokine (IL-10) were performed by an independent inves-
tigator blinded to the patients’ status (knee osteoarthritis or
healthy volunteers).
2.4. Statistics. Kolmogorov-Smirnov test and the observation
of the morphology of the histogram were used to test for a
normal distribution for all studied variables.
Quantitative characteristics with use of summary
measures (median, interquartile interval) were compared
between groups using Mann-Whitney 𝑈 test. Correlations
between age, pain duration, VAS, WOMAC scores, and
the PPT values were evaluated using scatter plots and
Spearman’s rank correlation coefficients. Stepwise multiple
linear regression models analyzed the relationships of VAS,
WOMAC subscales, and the PPT measures. Napierian
logarithm transformation was used to stabilize variability of
serum cytokine values. Analyses were performed using SPSS
software, version 15 (SPSS, Chicago, IL). 𝑃 values less than
0.05 (2-tailed) were considered significant.
3. Results
Mean age values of symptomatic patients (71.23 ± 7.62 years,
𝑛 = 53 (women)) and controls (68.21 ± 7.17 years, 𝑛 =
48, 2 men and 46 women) were not significantly different
(Table 1). All patients reported pain duration of at least 24
months (median, 96 months; range 36–150). About the use
of drugs in the group of OA knee individuals, 36 were taking
drugs, 22 with several medications such as antidepressants
and antihypertensive, among other items, and 14 were using
mediation analgesic. In the control group, 41 were taking
several medications such as antidepressants and antihyper-
tensive, among others.
3.1. Function and Pain. Mean WOMAC (pain, stiffness, and
function) scores in the OA patients were 10.90 ± 2.35, 4.20 ±
2.35, and 42.53 ± 14.59, respectively. Mean pain intensity in
the OA patients was 7.6 cm ± 1.59.
Knee OA patients showed lower PPTs compared to the
matched controls (𝑃 < 0.05) in all 24 muscular, ligamentous,
and subcutaneous points tested, both at the knees and at
distant sites (Table 2).
3.2. Blood Samples. Serum levels of IL-8 and TNF-𝛼 were
similar between patients and controls (Table 2). IL-6 (𝑃 =
0.031) and IL-10 (𝑃 = 0.030) levels were significantly elevated
in patients (Table 3).
3.3. Correlation Analysis. Correlation analyses of variables
are given in Table 4. Both IL-6 and IL-10 correlated positively
Table 1: Comparison of age and BMI (body mass index) between
the knee osteoarthritis (OA) and healthy control groups.
Knee OA Control 𝑃
𝑁 53 48
Age (years) 71.23 ± 7.62 68.21 ± 7.17 0.066
BMI (kg/cm2) 28.33 ± 5.95 27.42 ± 4.86 0.55
Note: values are presented as mean and standard deviation (SD). Kg:
kilogram. Cm: centimeter. BMI: body mass index.
with VAS and WOMAC scores for rigidity. Only IL-6 corre-
lated positively withWOMAC scores for pain. IL-6 and IL-10
did not correlate with any PPT measurements.
PPTs from muscular, ligamentous, or subcutaneous
sources showed themost consistent positive associationswith
TNF-𝛼 (Table 4).
For the pinch and roll cutaneous assessment, consistent
positive associations were found with TNF-𝛼 (Table 4).
3.4. Regression Analysis. Stepwise analysis revealed that a
combination of three variables added gain to the equation.
Besides VAS, combined PPT values over pes anserinus and
supraspinous ligaments at L1-L2 were the best predictors
(𝑅2 = 0.244) for serumTNF-𝛼 (Tables 4 and 5). For serum IL-
6, we found that WOMAC rigidity and VAS could be added
to the equation (𝑅2 = 0.186) (Tables 4 and 5).
We could not find any predictors for serum IL-8 or IL-10
(Tables 4 and 5).
4. Discussion
4.1. Main Findings. The present cross sectional observa-
tional study (i) explored the serum concentration of proin-
flammatory cytokines (IL-6, IL-8, and TNF-𝛼) and anti-
inflammatory cytokines (IL-10) in patients with knee OA and
healthy controls and (ii) associated those with clinical pain
manifestations and pain hyperalgesia as assessed by PPTs and
function. OA patients presented spreading sensitization as
assessed by pressure pain hyperalgesia from all the structures
investigated. IL-6 and IL-10 were higher in the knee OA
patients compared with matched controls. As an exploratory
study, we have not corrected for multiple analyses, and
therefore, for 30 comparisons, two positive results can be by
chance.
4.2. Cytokines Profile. Cytokines are glycoproteins of light
molecular weight, responsible for the communication among
cells of the immune system [29]. Several authors identified
the correlation of higher levels of serum cytokines and knee
OA, such as IL-6, TNF-𝛼, and TNF-𝛼 soluble receptors
sTNFR1 and sTNFR2, and C-reactive protein (CRP) [15, 30].
Classically, increased levels of proinflammatory cytokines are
related to development and progression of OA due to upreg-
ulation of metalloproteinase gene expression, stimulation of
reactive oxygen species production, alteration of chondrocyte
metabolism, and increased osteoclastic bone reabsorption
[15, 30–33].
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Table 2: Pressure pain threshold (PPT) values from the assessed structures.
Group
Variable Healthy control Knee OA Mean difference CI (95%) 𝑃 Cohen’s 𝑑
Mean SD 𝑁 Mean SD 𝑁 Lower Upper
Vastus M 6.00 2.08 48 3.30 1.81 53 2.70 1.93 3.47 <0.001 1.38
Adductor L 4.97 2.20 48 2.73 1.44 53 2.24 1.51 2.97 <0.001 1.21
Rectus fem 7.44 2.29 48 4.19 2.18 53 3.25 2.37 4.13 <0.001 1.45
Vastus L 6.13 2.09 48 3.47 2.10 53 2.66 1.83 3.49 <0.001 1.27
Tibialis ant 7.43 2.53 48 4.04 2.10 53 3.39 2.48 4.31 <0.001 1.46
Peroneus 7.40 2.33 48 4.21 2.96 53 3.19 2.13 4.25 <0.001 1.20
Gracilis 5.97 2.47 48 2.82 1.89 53 3.15 2.28 4.01 <0.001 1.43
Iliopsoas 6.45 3.36 48 3.50 1.34 53 2.95 1.96 3.95 <0.001 1.15
Quadratus L 6.86 2.04 48 4.10 1.86 53 2.77 2.00 3.54 <0.001 1.42
Pes anserinus 5.40 2.49 48 2.75 2.01 53 2.65 1.76 3.55 <0.001 1.17
Popliteus 7.05 2.36 48 3.87 2.20 53 3.18 2.28 4.08 <0.001 1.39
Lig L1-L2 7.98 3.12 48 4.46 2.07 53 3.52 2.48 4.55 <0.001 1.33
Lig L2-L3 8.38 3.11 48 4.37 2.21 53 4.01 2.95 5.06 <0.001 1.49
Lig L3-L4 8.09 3.10 48 4.58 2.31 53 3.51 2.44 4.58 <0.001 1.29
Lig L4-L5 8.29 2.89 48 4.64 2.10 53 3.65 2.66 4.64 <0.001 1.44
Lig L5-S1 8.70 2.98 48 4.42 2.27 53 4.28 3.24 5.32 <0.001 1.62
Lig S1-S2 8.72 3.21 48 4.90 2.81 53 3.82 2.63 5.01 <0.001 1.27
PRL1 3.79 2.11 48 2.39 3.45 53 1.40 0.25 2.54 <0.001 0.40
PRL2 3.67 1.83 48 1.77 1.33 53 1.90 1.27 2.53 <0.001 1.19
PRL3 4.26 1.74 48 2.01 1.34 53 2.25 1.64 2.86 <0.001 1.45
PRL4 5.58 2.17 48 2.95 1.77 53 2.63 1.85 3.41 <0.001 1.33
PRL5 5.09 1.98 48 2.47 1.58 53 2.62 1.92 3.33 <0.001 1.46
PR S1 5.51 1.59 48 3.02 1.59 53 2.50 1.87 3.12 <0.001 1.57
PR S2 4.80 1.92 48 2.77 1.49 53 2.03 1.35 2.70 <0.001 1.18
OA: osteoarthritis; Vastus M: vastus medialis; Adductor L: adductor longus; Rectus fem: rectus femoris; Vastus L: vastus lateralis; Tibialis ant: tibialis anterior.
PR: pinch and roll maneuver; Lig: supraspinous ligaments; Quad L: quadratus lumborum; L: lumbar; S: sacral.
SD: standard deviation; CI: confidence interval;𝑁: number; 𝑃: probability of significance.
Table 3: Comparison of cytokine concentrations between groups.
Variable Group Mean SD Median Quartile 1 Quartile 3 𝑁 𝑃
TNF𝛼 (pg/mL)
Healthy 1.40 1.02 1.29 0.0 2.8 48 0.457
Knee OA 2.20 4.52 1.30 1.1 1.5 53
All 1.82 3.36 1.26 0.0 24.2 101
IL-10 (pg/mL)
Healthy 0.89 0.87 1.30 0.0 2.3 48 0.030
Knee OA 1.58 2.36 1.17 0.0 1.2 53
All 1.25 1.84 1.09 0.0 15.7 101
IL-6 (pg/mL)
Healthy 2.55 1.06 2.9 2.3 4.0 48 0.031
Knee OA 4.38 4.61 2.4 1.7 3.1 53
All 3.48 3.53 2.50 1.2 19.3 101
IL-8 (pg/mL)
Healthy 9.72 5.28 8.80 5.4 16.0 48 0.984
Knee OA 10.56 8.51 9.00 6.2 12.7 53
All 10.16 7.14 8.83 0.0 53.5 101
OA: osteoarthritis; Healthy: healthy control; IL: interleukin; TNF: tumor necrosis factor; SD: standard deviation;𝑁: number of subjects; 𝑃: probability.
Several authors have described the association of disabil-
ity, measured by the WOMAC scores, with higher levels of
proinflammatory cytokines [14, 15, 18, 34]. TNF has been
compared to other proinflammatory cytokines and shown
to be elevated in elderly patients with knee osteoarthritis
[6, 35, 36]. Regarding knee OA, the most commonly mea-
sured cytokines in the literature are IL-6 and TNF-𝛼 [6,
37, 38]. Similar to previous reports [6, 35, 39], we observed
that serum levels of IL-6 had a twofold increase in patients
when compared to controls, comparable to a study that
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Table 4: Correlation among cytokines, age, pain duration, VAS,
WOMAC scores, and PPT values over 24 anatomical structures.
Variables TNF-𝛼 IL-10 IL-6 IL-8
Age
Spearman∗ −0.154 −0.019 0.016 −0.006
𝑃 0.123 0.854 0.873 0.954
𝑁 101 101 101 101
Pain duration
(months)
Spearman∗ −0.039 0.185 0.166 −0.001
𝑃 0.706 0.070 0.105 0.993
𝑁 97 97 97 97
VAS
Spearman∗ −0.029 0.203 0.238 0.020
𝑃 0.774 0.042 0.017 0.842
𝑁 101 101 101 101
WOMAC
pain
Spearman∗ −0.145 0.177 0.251 0.019
𝑃 0.151 0.078 0.012 0.850
𝑁 100 100 100 100
WOMAC
rigidity
Spearman∗ −0.050 0.271 0.303 0.059
𝑃 0.626 0.007 0.002 0.562
𝑁 99 99 99 99
WOMAC
difficulties
Spearman∗ −0.134 0.166 0.192 0.013
𝑃 0.182 0.097 0.055 0.896
𝑁 101 101 101 101
Vastus M
Spearman∗ 0.283 0.075 −0.070 0.113
𝑃 0.004 0.453 0.488 0.259
𝑁 101 101 101 101
Adductor L
Spearman∗ 0.337 0.054 −0.076 0.097
𝑃 0.001 0.589 0.449 0.335
𝑁 101 101 101 101
Rectus A
Spearman∗ 0.229 0.034 −0.056 0.133
𝑃 0.021 0.737 0.580 0.185
𝑁 101 101 101 101
Vastus L
Spearman∗ 0.252 −0.006 0.015 0.154
𝑃 0.011 0.955 0.880 0.124
𝑁 101 101 101 101
Tibialis ant
Spearman∗ 0.236 −0.067 −0.065 0.096
𝑃 0.017 0.507 0.519 0.338
𝑁 101 101 101 101
Peroneal
Spearman∗ 0.322 0.001 −0.075 0.067
𝑃 0.001 0.992 0.456 0.503
𝑁 101 101 101 101
Pes anserinus
Spearman∗ 0.339 0.113 0.009 0.099
𝑃 0.001 0.259 0.932 0.326
𝑁 101 101 101 101
Gracilis
Spearman∗ 0.322 0.050 −0.031 0.101
𝑃 0.001 0.623 0.761 0.316
𝑁 101 101 101 101
Iliopsoas
Spearman∗ 0.136 −0.098 −0.060 −0.058
𝑃 0.175 0.330 0.554 0.564
𝑁 101 101 101 101
Quad L
Spearman∗ 0.228 −0.080 −0.087 −0.030
𝑃 0.022 0.424 0.384 0.764
𝑁 101 101 101 101
Lig L1-L2
Spearman∗ 0.204 −0.122 −0.032 0.084
𝑃 0.041 0.223 0.750 0.406
𝑁 101 101 101 101
Table 4: Continued.
Variables TNF-𝛼 IL-10 IL-6 IL-8
Lig L2-L3
Spearman∗ 0.192 −0.100 −0.031 0.034
𝑃 0.055 0.322 0.762 0.733
𝑁 101 101 101 101
Lig L3-L4
Spearman∗ 0.139 −0.117 −0.068 0.037
𝑃 0.165 0.243 0.496 0.711
𝑁 101 101 101 101
Lig L4-L5
Spearman∗ 0.187 −0.091 −0.034 0.098
𝑃 0.061 0.367 0.737 0.330
𝑁 101 101 101 101
L5-S1
Spearman∗ 0.188 −0.045 −0.048 0.102
𝑃 0.060 0.656 0.635 0.312
𝑁 101 101 101 101
Lig S1-S2
Spearman∗ 0.171 −0.100 −0.067 0.081
𝑃 0.087 0.318 0.504 0.420
𝑁 101 101 101 101
Popliteus
Spearman∗ 0.266 −0.102 −0.067 0.056
𝑃 0.007 0.308 0.503 0.581
𝑁 101 101 101 101
PRL1
Spearman∗ 0.328 0.089 −0.077 0.057
𝑃 0.001 0.377 0.445 0.574
𝑁 101 101 101 101
PRL2
Spearman∗ 0.323 0.052 −0.063 0.123
𝑃 0.001 0.607 0.529 0.221
𝑁 101 101 101 101
PRL3
Spearman∗ 0.313 0.017 −0.046 0.059
𝑃 0.001 0.870 0.645 0.559
𝑁 101 101 101 101
PRL4
Spearman∗ 0.253 −0.061 −0.094 0.138
𝑃 0.011 0.547 0.349 0.169
𝑁 101 101 101 101
PRL5
Spearman∗ 0.278 −0.049 −0.013 0.073
𝑃 0.005 0.627 0.896 0.470
𝑁 101 101 101 101
PR S1
Spearman∗ 0.275 −0.104 −0.151 −0.026
𝑃 0.005 0.303 0.132 0.798
𝑁 101 101 101 101
PR S2
Spearman∗ 0.221 0.000 −0.068 −0.008
𝑃 0.026 0.998 0.497 0.938
𝑁 101 101 101 101
∗Spearman’s rank correlation coefficients.
Vastus M: vastus medialis; Adductor L: adductor longus; Rectus A: rectus
femoris; Vastus L: vastus lateralis; Tibialis ant: tibialis anterior; PR: pinch and
roll maneuver; Lig: supraspinous ligaments; Quad L: quadratus lumborum;
L: lumbar; S: sacral; IL: interleukin; TNF: tumor necrosis factor; WOMAC:
Western Ontario and McMaster Universities Arthritis Index; 𝑟: Spearman
correlation; 𝑃: probability.
showed increased IL-6 in patients with more severe disease
as measured by radiologic knee OA findings [6]. On the
other hand, serum concentrations of the other cytokines
are very heterogeneous to draw any conclusions. We also
demonstrated that symptomatic patients presented less resis-
tance to algometer-induced PPT than did the healthy controls
in all 24 muscular, ligamentous, and subcutaneous points
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Table 5: Stepwise multiple linear regression models for IL-6 and
TNF-𝛼 and age, VAS, WOMAC pain subscale, WOMAC rigidity
subscale, WOMAC physical activity subscale, and pressure pain
threshold values (in kg/cm2) in 24 studies structures.





(Constant) 0.961 0.125 <0.000
WOMAC rigidity 0.157 0.034 <0.000
VAS L 0.050 0.019 0.012





(Constant) 0.356 0.189 0.062
Pes anserinus 0.167 0.033 0.000
VAS 0.049 0.018 0.007
Ligaments L1-L2 −0.059 0.027 0.032
L: left.
tested, not only at the knees. Both IL-6 and IL-10 correlated
positively with VAS and WOMAC scores for rigidity. Only
IL-6 correlated positively with WOMAC pain scores.
In fact, many have investigated the effect of different
presentations of OA on the serum or intra-articular lev-
els of cytokines [6, 14–16]. However, to the best of our
knowledge, this is the first report regarding the association
between serum proinflammatory cytokines and PPTs that
are located further beyond the painful area at the involved
joint.This indicates a sclerotome-wide phenomenon that can
be explained only neurologically. On the other hand, the
lack of relation between this particular cytokine and pain
duration, WOMAC scores, or VAS remains to be clarified.
Additionally, since cytokine IL-10 was not detectable in the
cerebrospinal fluid of patients with knee OA, the concept of
central sensitization as an importantmechanism in the causal
chain of disability would be noteworthy [40]. Several authors
have already demonstrated that proinflammatory mediators
as interleukins are increased in fibromyalgia patients [41, 42].
It seems that chronic pain, hyperalgesia, and fatigue are
associated with increased levels of IL-6 and IL-8 in these
patients [18, 41]. Similarly, tissue lesionmay, inmost cases, not
be themajor issue determining loss of function and quality of
life in OA.
Interestingly, muscle tender points and lower tolerance to
pressure areas have higher levels of TNF-𝛼 when compared
to healthy individuals without spontaneous pain or asymp-
tomatic subjects [43–45]. In subjects with spontaneous pain,
areas distant from the site of pain also showed a significant
increase of these chemical mediators [45]. Cytokine produc-
tion has also been demonstrated in nonimmune tissue under
special conditions such as acute inflammation. Production of
proinflammatory cytokines such as IL-1-𝛽, IL-6, and TNF-
𝛼 has recently been found in skeletal muscle tissue during
special conditions such as endotoxemia [46]. However, the
influence of hyperalgesia found in muscle tissues of patients
with OA on serum cytokines has not been determined,
although leaking from local microenvironment could be a
possible mechanism.
Still, we must remember that the process called inflam-
maging indicating a regulation of the inflammatory response
that occurs with aging can result in the production of inflam-
matory cytokines, which generates a low level of chronic and
systemic proinflammatory state [47, 48]. This may occur due
to the presence of chronic diseases associated with aging such
asOA, as well as other conditions such as obesity and physical
inactivity [47].
A possible source of local cytokine production, different
from the inflammatory cells, may be the adipose tissue. It
is known that adipose tissue produces and secretes several
proinflammatory cytokines, including IL-6 and TNF-𝛼 [49].
Despite the lack of correlations between IL-6 and the PPT
values over any of the assessed tissues, we observed that
PPT value over supraspinous ligament L1-L2 combined with
pes anserinus and VAS can predict serum levels of TNF-𝛼.
Yet increased production and secretion of proinflammatory
cytokines (biomarkers) by adipose cells have been hypoth-
esized as the role played by obesity as a risk factor for OA
[50]. According to Livshits et al. [6], when inflammation
occurs, cytokine profile changes and seems to be influenced
by obesity and aging [15, 16]. In fact, we have recently
demonstrated that aging may play a role in cytokine profile, a
finding not so extensively addressed in the literature and that
should be further investigated [51]. In the elderly population,
body metabolism and composition, as well as the response
to acute inflammation, may be altered and influenced in
a different pattern by cytokines than in the acute-phase
response, all of which are altered with increasing age [52].
TNF-𝛼 seems to act as a biomarker of physiologic status
and a major predictor of strength and functional status in
the elderly [6]. IL-1𝛼, IL-1𝛽, and TNF-𝛼 seem to induce
production of IL-6 [52]. To the best of our knowledge, the
contribution of inflammatory factors such as IL-6 and TNF-𝛼
to the involvement of structures outside the knee joint has not
been adequately explored yet, in particular, the correlation
of structures that are innervated by the same spinal nerve
constituting the metameres.
Our study had some limitations. First, we did notmeasure
other cytokines such as IL-1 or IL-Ra, due to the budget of the
study. Another item is the lack of radiographic evaluation of
the control subjects. But it is noteworthy that, in the clinical
evaluation of these patients, absence of pain was observed
and evaluated. However, further studies with radiographic
classification of healthy volunteers, with other cytokines,
are needed to confirm our findings and to explore the
local production of cytokines by skeletal muscle (myocytes),
adipose cells, and the surrounding connective tissue.
5. Conclusion
This study showed that serum levels of IL-6 and IL-10 were
higher in knee OA than in healthy controls. A positive asso-
ciation between IL-10 and IL-6 with VAS and WOMAC for
pain and rigidity scores was found. These findings align with
a physiopathological understanding of pain and functionality
International Journal of Inflammation 7
that surpasses the one which currently provides basis for
therapeutics in OA.
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